Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 88

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 88
---
 Light. (A), un-treated mice; (B), mice treated with LRPE-Nano-mupirocin; (C,D), smears of LRPE-Nano-mupirocin observed under fluorescent light. Scale bar = 50 μm.

Figure 10: Mupirocin in Vaginal Secretions. Mupirocin concentration (free (non-liposomal) plus liposomal) in vaginal secretions (ng/g) and plasma (ng/mL) following IP administration of Nano-mupirocin 50 mg/kg (mean ± SE). (n = 5 for swab samples and n = 4 for plasma samples).

<div align='center'>55</div>

Substantial pre-clinical research of the novel
Nan-Mupirocin formulation has indicated that this novel approach may allow for a new potent therapy to combat bacteria listed as serious
and urgent threats by the Center for Disease Control (CDC), subject to clinical trials. Management believes that the novel formulation
of Nano-Mupirocin may hold the potential to serve as a highly potent systemic therapy for serious life-threatening infections, such as
resistant Gonorrhea, MRSA induced endocarditis, or sepsis.

Key facts about mupirocin and findings from preclinical
research on Nano-Mupirocin:

| - | Broad antibacterial activity.                                                                     
 The antibacterial spectrum of mupirocin is well studied. Mupirocin is registered as a             
 topical ointment (Bactroban™ by GlaxoSmithKlein). Mupirocin is known to be highly effective       
 against staphylococci, streptococci, certain Gram-negative bacilli, including N. gonorrhoea       
 and a broad range of Gram-positive bacteria. [1] Mupirocin’s activity is enhanced at              
 acidic pH levels and is not significantly influenced by inoculum size, although its effectiveness 
 decreases in serum due to high protein binding (95%). Its primary mechanism involves inhibiting   
 RNA and protein synthesis by targeting the isoleucine-binding site on the isoleucyl-transfer-RNA  
 synthetase enzyme in bacteria. This unique mode of action, different from other antibiotics,      
 reduces the likelihood of cross-resistance.[2]                                                    |

| - | Spectrum and cellular uptake:                                                                      
 Pre-clinical studies have indicated that Nano-Mupirocin has demonstrated a high level              
 of tolerance, including activity against methicillin-resistant Staph